Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Aram Mangasarian M.B.A., Ph.D. | CEO & Member of Management Board | 527.25k | -- | 1970 |
| Ms. Ewelina Staniuk | Senior Director of Investor Relations & Business Development | -- | -- | -- |
| Ms. Karen Ophoff | VP of HR & Legal and General Counsel | -- | -- | -- |
| Dr. Jarl Ulf Jungnelius M.D., Ph.D. | Chief Medical Officer | -- | -- | 1951 |
| Dr. Heike Balzer | Senior Vice President of Finance | -- | -- | -- |
| Dr. Dirk Eulberg M.B.A. | Senior Vice President of Project Management & Preclinical Development | -- | -- | -- |
TME Pharma N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 13
Description
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. The company is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is headquartered in Berlin, Germany.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available